Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Versartis, Inc. (VSAR) in Focus: Stock Moves 11.5% Higher

Versartis, Inc. VSAR was a big mover last session, as the company saw its shares rise over 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $18.05–$20.95 in the past one-month time frame, witnessed a sharp increase on Friday.

The company has seen no positive and three negative estimate revisions in the past two months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.  

Versartis currently has a Zacks Rank #2 (Buy) while its Earnings ESP is positive.

Versartis, Inc. Price and Consensus

A better ranked stock in the Medical sector is Aetna Inc. AET which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is VSAR going up? Or down? Predict to see what others think: Up or Down

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Versartis, Inc. (VSAR): Free Stock Analysis Report
 
Aetna Inc. (AET): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research